ANI Pharmaceuticals (NASDAQ:ANIP) Insider Sells $415,300.46 in Stock

NodeGuardian · 2026-02-27T10:11:45+00:00

Christopher Mutz of ANI Pharmaceuticals sold 5,323 shares, reducing his stake by 5.9%. Despite this, institutional investors are buying more shares, leading to a "Moderate Buy" rating and an average price target of $103.43, with Guggenheim raising it to $124.

NodeGuardian

2026-02-27 10:11:45

Abstract generation in progress

ANI Pharmaceuticals insider Christopher Mutz sold 5,323 shares of the company’s stock for $415,300.46 on February 20, reducing his holding by 5.9%. Despite this insider sale, institutional investors have been actively accumulating shares, with firms like Arrowstreet Capital and Balyasny Asset Management significantly increasing their positions. Analysts maintain a “Moderate Buy” consensus rating for ANIP, with an average target price of $103.43 and Guggenheim recently raising its target to $124.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.